Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.
In addition to two oral presentations and two poster presentations on Gaucher disease, the company will present findings from a re-analysis of disease stage progression in Globoid Cell Leukodystrophy (GLD).
Dr. Michael West from Dalhousie University in Halifax, Canada will also present head-to-head REPLAGAL 0.2 mg/kg and Fabrazyme 1.0 mg data, sponsored by the Canadian Fabry Disease Initiative (CFDI).
“We are excited to participate in this very important scientific meeting,” said Whaijen Soo, MD, PhD, Senior Vice President, Research and Development, Shire Human Genetic Therapies (HGT).
“Shire continues to deliver on its promise to pursue the development and commercialization of treatments which will enable people with life-altering conditions to lead better lives and we’re looking forward to sharing data which underscores the success of our commitment in the area of rare genetic diseases.”